treatment-resistant depression

Esketamine Was Not “Cost-Effective” for Treatment-Resistant Depression in Hong Kong

by
Esketamine Lost the Cost-Effectiveness Race in Hong Kong

Esketamine Lost the Cost-Effectiveness Race in Hong Kong TL;DR: A 5-year Hong Kong model found esketamine plus an antidepressant bought only a small quality-adjusted survival gain at US$29,061 per patient, leaving it behind cheaper third-line options like combination therapy. Key Findings Seven third-line strategies modeled: A Markov cohort model followed adults with treatment-resistant depression in …

Read more

Ketamine Effective for Treatment-Resistant Depression: No Added Benefit from Music

by
Ketamine Improved Severe Depression Without Music Support

TL;DR: A 2026 randomized trial in The British Journal of Psychiatry found 6 ketamine infusions improved severe treatment-resistant depression, but curated music added no measurable benefit; higher mystical-experience scores still predicted the next session’s depression outcome. Key Findings MADRS fell 11.8 points by week 4: Scores dropped from 31.5 to 19.7 (d = 1.2, p …

Read more

Ketamine Restored Reward Bias in Depression and Stressed Rats

by
Ketamine Restored Reward Bias Across Species

Ketamine Restored Reward Bias Across Species TL;DR: Ketamine restored reward-learning bias in both treatment-resistant depression and chronically stressed rats while leaving basic discrimination unchanged. Key Findings Reward bias increased: Ketamine significantly increased response bias toward the more frequently rewarded stimulus in both species. Healthy-control levels returned: The reward-bias effect reached levels comparable with healthy controls …

Read more